mRNA and cytokine receptors in cells from patients with HES.
Introduction

Patient 1 Idiopathic hypereosinophilic syndrome (HES) is a sustained
A 39-year-old white man presented at another institution in (longer than 6 months) peripheral eosinophilia characterized May 1993 with a several-week history of left arm tingling, difby more than 1500 eosinophils per cubic millimeter (mm 3 ). fuse myalgia, dyspnea on exertion, diffuse papular rash, and The differential diagnosis includes all other etiologies of general fatigue. Physical examination revealed a papular skin eosinophilia, such as parasitic infection, allergy, or neoplasm.
rash. The WBC count was 187 000/mm 3 with 69% eosinoPatients should have signs and symptoms of organ infiltration phils and 13% neutrophils. Hemoglobin was 12.3 g/dl. Plateby eosinophils. 1 An excellent review of HES was published by let count was 122 000/mm 3 . Bone marrow biopsy showed Weller and Bubley. 2 45% eosinophils with no immature leukemic cells. Karyotypic Idiopathic HES is more common in men than in women, analysis showed 46 XY without the Philadelphia chromosome. with a ratio of 9:1. The age of onset is between 20 and 50 Chest X-ray revealed no abnormalities. A magnetic resonance years. Peripheral blood differential counts usually show 30-imaging (MRI) scan of the brain revealed multiple small 70% eosinophils with a white blood cell (WBC) count of lesions in the white matter of the centrum semiovale. The 25 000/mm 3 . Bone marrow biopsies show eosinophilia with patient received a short course of oral prednisone, but was no dysplasia or blasts. Findings of cytogenetic analysis are unable to tolerate it because of nervousness. usually normal. Eosinophil infiltration in tissues causes
In June 1993, the patient had an extensive work-up for hypdamage to the heart, skin, and nervous system and results in ereosinophilia. Anti-nuclear antibody titer, Lyme titer, stool for cardiomyopathy, rash, and various neurological symptoms. ova and parasites. Toxoplasma IgG titer, and Trichinella IgG The etiology of idiopathic HES is unknown, but there is evititer were all negative. Aldolase, creatine phosphokinase, dence that cytokines produced by helper T cells stimulate the serum IgE level, and vitamin B12 and folic acid levels were proliferation of eosinophils. 4 It has been reported that interleuwithin normal limits. An echocardiogram and upper gastrokin (IL)-5, IL-3, and granulocyte-macrophage colony-stimulatintestinal series revealed no abnormalities. Computed tomoing factor (GM-CSF) work synergistically in the proliferation graphic (CT) scan of the abdomen showed mild splenomegaly. of eosinophils, and IL-5, particularly, is considered to play a An electromyogram indicated carpal tunnel syndrome. A musmajor role. 3 cle biopsy showed no eosinophilic fascitis. Abdominal ultrasound showed only splenorevealed unsteady gait with poor coordination and a systolic megaly. After an extensive work-up, the patient was diagejection murmur along the left sternal border to the apex.
nosed as having idiopathic HES. The patient was treated with Echocardiogram showed a left ventricular mass with an ejechigh-dose interferon-␣ subcutaneously. The WBC count stabition fraction (EF) of 51%. WBC count was 37 000/mm 3 with lized to 10 000/mm 3 with 10-20% eosinophils. However, 38% eosinophils. Bone marrow aspirate and biopsy showed after 1 year the therapy was discontinued because of low-98% cellularity with 50.4% eosinophils and normal cytogengrade fever, weight loss and severe weakness. The patient was etics. Hydroxyurea was continued at 2 g/day with 30 mg/day then started on steroid and hydroxyurea until 1994. In April prednisone, which reduced the WBC count to 7000/mm 3 and 1994, he was found to have congestive heart failure due to provided some symptomatic relief. Hydroxyurea was then cardiac involvement of the eosinophils. He was started on reduced to 1 g/day and prednisone to 15 mg/day. low-dose cytarabine. However, prolonged myelosuppression When the peripheral blood count of eosinophils increased resulted in Staphylococcus sepsis. Because of uncontrolled to 5670/mm 3 in March 1994, hydroxyurea was increased to leukocytosis with hypereosinophilia, in May 1995, 2-CdA 2.5 g/day and prednisone to 25 mg/day. In late March 1994, (0.1 mg/kg continuous infusion over 7 days) was initiated. the patient maintained a WBC count of 10 000/mm 3 with hyAfter the first cycle of 2-CdA, the WBC count went down from droxyurea of 1 g/day. However, on 12 April 1994, the patient 73 000 to 13 400/mm 3 with 5% eosinophils at day 42. There developed progressive shortness of breath associated with carwas also a significant decrease in the size of the spleen. Howdiomyopathy and progressive thrombocytopenia (36 000 ever, there was no change in cardiac function. The patient platelets/mm 3 ) and anemia (hemoglobin of 6.4 g/dl). Highrequired intense cardiac management secondary to right-side dose cytarabine (2 g/m 2 intravenously every 12 h for four heart failure. Then a second cycle of 2-CdA at the same dosdoses) was given from 21 April 1994. Because the patient's age was delivered in August 1995. However, a third cycle was condition was terminal, 'do not resuscitate' orders were writnot given because of prolonged anemia and myelosuppression ten. The WBC count decreased to 3500/mm 3 , but a bone marafter the second cycle. row biopsy performed 2 weeks after high-dose cytarabine showed 60.8% eosinophils. After high-dose cytarabine was ineffective, the patient was restarted on hydroxyurea (3 g/day) and prednisone (20 mg/day) for palliation.
Materials and methods The patient's cardiac and cognitive functions continued to deteriorate. The combination of 2-CdA and cytarabine was started on 2 June 1994. This regimen consisted of 2-CdA Purified RNA samples from fluorescence-activated cell-sorted (12 mg/m 2 /day) by continuous infusion for 5 days and cytaracell populations were quantitated using a DU-640 spectrobine (1 g/m 2 ) intravenously over 2 h daily on days 1, 3, 4, 5 photometer (Beckman Instruments, Fullerton, CA, USA). A and 6. The patient developed prolonged neutropenia from day reverse transcription kit was used to synthesize cDNA accord-7, complicated by congestive heart failure, fever and mental ing to the manufacturer's instructions (Boehringer Mannheim, status changes. His WBC count started to recover around 29 Indianapolis, IN, USA). One microgram of total RNA template days after initiation of this regimen. On day 35, the WBC was was used per 10 l of reverse transcription (RT) product. The 8800/mm 3 with no peripheral eosinophils. Bone marrow IL-5, tumor necrosis factor-␣ (TNF-␣), GM-CSF and ␤ 2 -aspirate and biopsy on day 36 showed only 1% eosinophils. microglobulin primers (CLONTECH Laboratories, Palo Alto, An echocardiogram in July 1994 showed an EF of 54% in M CA, USA) were synthesized on an ABI-392 oligo synthesizer mode with a left ventricular apical mass; there was no change (Perkin-Elmer, Foster City, CA, USA). PCR amplification and compared to the echocardiogram in April 1994, which detection were carried out as previously reported. 8 The bindshowed an EF of 56% in M mode. MRI scan of the brain did ing of cytokines to their receptors in CD3-, CD4-and CD8-not reveal any change since April 1994. Even though there labeling T cells was measured by using biotinylated IL-1␣, ILwas a persistent decrease in eosinophil count, the previous 1␤, IL-2, IL-3, IL-4, IL-6, IL-7, granulocyte colony-stimulating central nervous system and cardiac complications were irrefactor (G-CSF), GM-CSF and c-KIT ligand Fluorokines (R&D versible. A second course of 2-CdA/cytarabine was not given Systems, Minneapolis, MN, USA). 9, 10 Fluorescence was measbecause of the poor performance status of the patient. The ured using a FACScan flow cytometer (Becton Dickinson, San patient was transferred to hospice care. His peripheral eosinoJose, CA, USA) and was analyzed with LYSYS II software phils never exceeded 1680/mm 3 , and his bone marrow (Becton Dickinson), which provides the Kolmogorov-Smirnov eosinophils were never over 10.4%. He died in September model for user-independent analysis of overlapping fluor-1994.
escence distributions. 11 Results were expressed as D-values; values greater than 0.15 were considered positive.
Results
than 1000 neutrophils/mm 3 ) for 32 days. There were no eosinophils in the peripheral blood when the WBC count started to recover. The bone marrow had only 1% eosinophils Review of clinical course on day 36 and 10.4% eosinophils on day 54 (Figure 2) . The patient maintained a low absolute eosinophil count of less Both patients met the criteria for diagnosis of idiopathic HES than 1500/mm 3 for 3 months until he died. In the second based on prolonged eosinophilia with eosinophilic infiltration patient, there was once again a sustained decrease in the into the central nervous system and the heart. Other possible eosinophil count after 2-CdA alone was given, which was not causes of their eosinophilia were ruled out. The absence of obtained using the previous treatment, interferon and hydroximmature eosinophils in the peripheral blood, the lack of maryurea ( Figure 3 ). row blasts, and the absence of cytogenetic abnormalities excluded the diagnosis of eosinophilic leukemia. Normal vitamin B12 levels, normal bone marrow, and normal cytoCytokine expression and receptors genetic results excluded the diagnosis of myeloproliferative disorders.
We examined lymphocytes and eosinophils from two patients In the first patient, the patient's prior treatment included with idiopathic HES for mRNA expression of IL-5, GM-CSF steroids and hydroxyurea, but these regimens never supand TNF-␣. There was no increased mRNA expression of ILpressed the absolute eosinophil count below 1500/mm 3 or 5 or GM-CSF in CD3 + (sample 2), CD4 + (sample 1 or 2), and improved his clinical symptoms and signs. When the patient CD8 + (samples 1 or 2) cells or eosinophils (samples 1 or 2). received high-dose cytarabine, the WBC count decreased TNF-␣ was expressed in the eosinophils as expected, in CD4 + transiently to 3500/mm 3 . However, there were always circulcells and to a much lesser degree in CD8 + (sample 1) and ating eosinophils, and there was no change in the ratio of CD3 + (sample 2) cells. Loading of all samples were controlled eosinophils (42.4%) in the bone marrow (Figure 1 ). Following by ␤ 2 -microglobulin amplification (data not shown). 2-CdA and cytarabine, the patient developed neutropenia (less Table 1 
Discussion
The dysregulated proliferation of eosinophils in idiopathic HES without malignant transformation is possibly affected by helper T cells. Helper T cells are known to secrete several types of cytokines. 12 Two different types of helper T cells were recognized first in mice and more recently in humans. 13 Type 1 helper T cells produce IL-2 and interferon-␥. Type 2 helper T cells produce IL-4 and IL-5. IL-5 is an important factor for Response of bone marrow (BM), blood eosinophils/ WBCs, platelets and hemoglobin to cytarabine alone (patient 1).
Kolmogorov-Smirnov analysis.
Figure 2
Response of bone marrow (BM) and blood eosinophils/WBC, to 2-CdA plus cytarabine (patient 1).
the stimulation of eosinophil proliferation and maturation and these lymphocytes may be producing cytokines that stimulate leukemic cell proliferation. synergizes with GM-CSF and IL-3. Type 2 helper T cells are involved in certain allergic reactions, immunological diseases, There is currently no established treatment for idiopathic HES. Control of eosinophil count is the first step in avoiding infections, and lymphomas that cause eosinophilia. Cogan et al 4 reported recently the clonal proliferation of type 2 helper or delaying clinical sequelae. We report here the first use of 2-CdA for idiopathic HES. On the basis of Cogan et al's report T cells in a patient with idiopathic HES. This clonal proliferation was confirmed by clonal rearrangement of the betashowing the production of IL-5 by type 2 helper T cells, we hypothesized that 2-CdA may suppress helper T cells, which chain of the T cell-receptor gene. Also, there was highly increased production of IL-5 and IL-4 in these clonal T would decrease IL-5 secretion. Hence, eosinophilia would be controlled. The rationale of using interferon and cyclosporin lymphocytes. 4 New purine analogues, including 2-CdA and fludarabine, are for idiopathic HES is also based on the suppression of cytokine production by helper T cells. The combination of 2-CdA and currently used for chronic lymphocytic leukemia, hairy cell leukemia, and low-grade lymphoma.
14-16 2-Chlorodeoxyadenoscytarabine was chosen for an anticipated synergistic antiproliferative effect since the two agents act through different ine is particularly resistant to deamination. Its detailed action was reviewed by Saven and Piro. 17 The standard dosage given mechanisms and 2-CdA may increase intracellular Ara-CTP level.
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by continuous infusion in hairy cell leukemia is 0.1 mg/kg or 4 mg/m 2 /day for 7 days. This regimen is cycled every 4-5 In the first case, in a patient with idiopathic HES that was refractory to steroids, hydroxyurea and high-dose cytarabine, weeks. Major side-effects are bone marrow suppression, nausea, skin reaction, headache, fever, chills and general fatigue.
2-CdA plus cytarabine caused a very rapid and sustained decrease of circulating eosinophils. There was unfortunately The 2-CdA doses used in our cases are similar to the high end of the dose range used in hairy cell leukemia.
no clinical improvement in the patient following treatment with 2-CdA, probably due to advanced organ damage by proPatients receiving 2-CdA can develop significant immunosuppression with decreased peripheral B and T cells. The suplonged eosinophilic infiltration. In the second case, 2-CdA alone was given to test if eosinophils can be suppressed. pression of helper T cells after 2-CdA treatment can last up to 6-12 months, and fludarabine can suppress T cells in chronic Because of the prolonged myelosuppression from the first case, in the second case the 2-CdA was delivered at a dosage lymphocytic leukemia for even longer periods. 15, 18, 19 Estey et al 16 reported a decrease in helper T cells in all 15 of their comparable to that need for hairy cell leukemia. Again, a sustained decrease of eosinophils was observed. patients with hairy cell leukemia who received 2-CdA and a decrease of suppressor T cells in 12 of the 15 patients. The
As our therapeutic rationale was derived from the assumption that T cells play a major role in idiopathic HES, we major mechanism of 2-CdA's action against hairy cell leukemia probably involves suppression of DNA synthesis of leuattempted to confirm the results of Cogan et al 4 by measuring cytokine mRNAs by RT-PCR. However, RT-PCR did not show kemic cells. In addition, the suppression of helper and suppressor T cells may be relevant for the anti-leukemic effect, as any production of IL-5 or GM-CSF. Our results therefore sug-
